Journal List > Tuberc Respir Dis > v.64(6) > 1001236

TOOLS
Oh: Clinical Year in Review of COPD for Pulmonary Physicians
Review
Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2008; 64(6): 409-413.

Published online: 30 June 2008

DOI: https://doi.org/10.4046/trd.2008.64.6.409

Clinical Year in Review of COPD for Pulmonary Physicians

Yeon-Mok Oh, M.D.

Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicne, Seoul, Korea.

Address for correspondence: Yeon-Mok Oh, M.D. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicne, Asanbyeongwon-gil 86, Songpa-gu, Seoul 138-736, Korea. Phone: 82-2-3010-3136, Fax: 82-2-3010-6968, ymoh55@amc.seoul.kr

Copyright © 2008 The Korean Academy of Tuberculosis and Respiratory Diseases

Figures and Tables

Figure 1
Annual number of publication related to COPD.
trd-64-409-g001

References

1. Korea National Statistical Office, Republic of Korea [Internet]. c1996-. cited 2008 Mar. Daejeon: Korea National Statistical Office;Available from: http://www.nso.go.kr.
2. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med. 2005. 172:842–847.
3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006. 367:1747–1757.
4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007. 176:532–555.
5. PubMed [Internet]. 1950. cited 2008 Mar. Bethesda (MD): National Library of Medicine (US);Available from: http://www.ncbi.nlm.nih.gov/sites/entrez.
6. Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax. 2007. 62:237–241.
7. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007. 146:545–555.
8. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008. 177:19–26.
9. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007. 176:154–161.
10. Osman LM, Douglas JG, Garden C, Reglitz K, Lyon J, Gordon S, et al. Indoor air quality in homes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007. 176:465–472.
11. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008. 63:301–305.
TOOLS
Similar articles